GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.James Spicer, Luis Paz‐Ares, I. López Calderero et al.|Journal of Clinical Oncology|2012Cited by 0
Thrombo-embolic events in cancer patients with impaired renal functionIsmaı̈l Elalamy, Joëlle Nortier, J-L. Canon et al.|VUBIR (Vrije Universiteit Brussel)|2015Cited by 0